Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies, a biopharmaceutical company, has announced positive results from a study by Novartis Pharma which demonstrated the achievement of a suitable pharmacokinetic profile of a new oral formulation of parathyroid hormone using Emisphere's Eligen Technology.
Subscribe to our email newsletter
This initial study of 20 healthy postmenopausal female patients aged 40 to 70 years resulted in peak concentrations in the range of those obtained with the commercially available subcutaneous formulation Forteo (teriparatide). The plan is to continue the development program. This initial trial reported no significant adverse affects, no hypocalcaemia, and no drug-exposure related discontinuation.
Michael Novinski, president and CEO of Emisphere Technologies, said: “As with the development of any drug, these study results were very critical. They may confirm the formulation and the technology and set the stage for an important development plan which will now follow. Oral parathyroid hormone is a significant early-stage product to the Emisphere pipeline.”